{
  "ticker": "ALA",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959175",
  "id": "02959175",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250617",
  "time": "1111",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250617/pdf/06ktm6dvd6djx0.pdf",
  "summary": "**Summary of ASX Announcement (ALA - Arovella Therapeutics Limited):**  \n\n- **Section 708A Notice (Prior Placement):**  \n  - **Shares Issued:** 717,444 ordinary shares (no disclosure under Part 6D.2).  \n  - **Issue Date:** 16 June 2025.  \n  - **Compliance Confirmed:** Chapter 2M (financial reporting), sections 674/674A (continuous disclosure).  \n\n*No material capital markets or trading-impacting information beyond the share issuance details.*",
  "usage": {
    "prompt_tokens": 1326,
    "completion_tokens": 114,
    "total_tokens": 1440,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-17T01:30:04.979899"
}